Acrolein impairs the cholesterol transport functions of high density lipoproteins

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Chadwick, Alexandra C ^a   Holme, Rebecca L ^a   Chen, Yiliang ^b   Thomas, Michael J ^c   Sorci Thomas, Mary G ^c   Silverstein, Roy L ^a,b   Pritchard, Kirkwood A ^d   Sahoo, Daisy ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d Children's Hospital of Wisconsin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACROLEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR BI; CHOLESTEROL;

ANIMAL CELL; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; COS 7 CELL LINE; IMMUNOBLOTTING; IN VITRO STUDY; INCUBATION TIME; LIPID STORAGE; MACROPHAGE; MASS SPECTROMETRY; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; THIN LAYER CHROMATOGRAPHY; ANIMAL; C57BL MOUSE; CHLOROCEBUS AETHIOPS; COS CELL LINE; DRUG EFFECTS; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

MURINAE;

ACROLEIN; ANIMALS; BIOLOGICAL TRANSPORT; CERCOPITHECUS AETHIOPS; CHOLESTEROL; CHROMATOGRAPHY, THIN LAYER; COS CELLS; LIPOPROTEINS, HDL; MACROPHAGES; MICE; MICE, INBRED C57BL; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84927672521     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123138     Document Type: Article

References (66)

1. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011; 8: 222-232. doi: 10.1038/nrcardio.2010.222 PMID: 21304474
2. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968; 9: 155-167. PMID: 4868699
3. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996; 271: 518-520. PMID: 8560269
4. Glass C, Pittman RC, Civen M, Steinberg D. Uptake of high-density lipoprotein-associated apoprotein A-I and cholesterol esters by 16 tissues of the rat in vivo and by adrenal cells and hepatocytes in vitro. J Biol Chem. 1985; 260: 744-750. PMID: 3918032
5. Pittman RC, Knecht TP, Rosenbaum MS, Taylor CA Jr. A nonendocytotic mechanism for the selective uptake of high density lipoprotein-associated cholesterol esters. J Biol Chem. 1987; 262: 2443-2450. PMID: 2434485
6. Liu T, Krieger M, Kan HY, Zannis VI. The effects of mutations in helices 4 and 6 of ApoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport. J Biol Chem. 2002; 277: 21576-21584. PMID: 11882653
7. Gu X, Trigatti B, Xu S, Acton S, Babitt J, Krieger M. The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain. J Biol Chem. 1998; 273: 26338-26348. PMID: 9756864
8. Connelly MA, de la Llera-Moya M, Monzo P, Yancey PG, Drazul D, Stoudt G, et al. Analysis of chimeric receptors shows that multiple distinct functional activities of scavenger receptor, class B, type I (SR-BI), are localized to the extracellular receptor domain. Biochemistry. 2001; 40: 5249-5259. PMID: 11318648
9. Connelly MA, De La Llera-Moya M, Peng Y, Drazul-Schrader D, Rothblat GH, Williams DL. Separation of lipid transport functions by mutations in the extracellular domain of scavenger receptor class B, type I. J Biol Chem. 2003; 278: 25773-25782. PMID: 12730208
10. Papale GA, Nicholson K, Hanson PJ, Pavlovic M, Drover VA, Sahoo D. Extracellular hydrophobic regions in scavenger receptor BI play a key role in mediating HDL-cholesterol transport. Arch Biochem Biophys. 2010; 496: 132-139. doi: 10.1016/j.abb.2010.02.011 PMID: 20219439
11. Pittman RC, Steinberg D. Sites and mechanisms of uptake and degradation of high density and low density lipoproteins. J Lipid Res. 1984; 25: 1577-1585. PMID: 6397563
12. Ji Y, Jian B, Wang N, Sun Y, Moya ML, Phillips MC, et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem. 1997; 272: 20982-20985. PMID: 9261096
13. Pashkow FJ. Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention? Int J Inflam. 2011; 2011: 514623. doi: 10.4061/2011/514623 PMID: 21860805
14. Bonomini F, Tengattini S, Fabiano A, Bianchi R, Rezzani R. Atherosclerosis and oxidative stress. Histol Histopathol. 2008; 23: 381-390. PMID: 18072094
15. Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010; 30: 2311-2316. doi: 10.1161/ATVBAHA.108.179697 PMID: 21084697
16. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013; 7: 484-525. doi: 10.1016/j.jacl.2013.08.001 PMID: 24079290
17. Larach DB, deGoma EM, Rader DJ. Targeting high density lipoproteins in the prevention of cardiovascular disease? Curr Cardiol Rep. 2012; 14: 684-691. doi: 10.1007/s11886-012-0317-3 PMID: 22991041
18. Ferretti G, Bacchetti T, Negre-Salvayre A, Salvayre R, Dousset N, Curatola G. Structural modifications of HDL and functional consequences. Atherosclerosis. 2006; 184: 1-7. PMID: 16157342
19. Salmon S, Maziere C, Auclair M, Theron L, Santus R, Maziere JC. Malondialdehyde modification and copper-induced autooxidation of high-density lipoprotein decrease cholesterol efflux from human cultured fibroblasts. Biochim Biophys Acta. 1992; 1125: 230-235. PMID: 1571368
20. Raveh O, Pinchuk I, Schnitzer E, Fainaru M, Schaffer Z, Lichtenberg D. Kinetic analysis of copper-induced peroxidation of HDL, autoaccelerated and tocopherol-mediated peroxidation. Free Radic Biol Med. 2000; 29: 131-146. PMID: 10980402
21. Maziere JC, Myara I, Salmon S, Auclair M, Haigle J, Santus R, et al. Copper- and malondialdehyde-induced modification of high density lipoprotein and parallel loss of lecithin cholesterol acyltransferase activation. Atherosclerosis. 1993; 104: 213-219. PMID: 8141845
22. McCall MR, Tang JY, Bielicki JK, Forte TM. Inhibition of lecithin-cholesterol acyltransferase and modification of HDL apolipoproteins by aldehydes. Arterioscler Thromb Vasc Biol. 1995; 15: 1599-1606. PMID: 7583533
23. Bhatnagar A. Environmental Cardiology: Studying Mechanistic Links Between Pollution and Heart Disease. Circ Res. 2006; 99: 692-705. PMID: 17008598
24. Bonnefont-Rousselot D, Motta C, Khalil AO, Sola R, La Ville AE, Delattre J, et al. Physicochemical changes in human high-density lipoproteins (HDL) oxidized by gamma radiolysis-generated oxyradicals. Effect on their cholesterol effluxing capacity. Biochim Biophys Acta. 1995; 1255: 23-30. PMID: 7893734
25. Shao B, Heinecke JW. Impact of HDL oxidation by the myeloperoxidase system on sterol efflux by the ABCA1 pathway. J Proteomics. 2011; 74 (11): 2289-2299. doi: 10.1016/j.jprot.2011.04.001 PMID: 21501700
26. McCall MR, van den Berg JJ, Kuypers FA, Tribble DL, Krauss RM, Knoff LJ, et al. Modification of LCAT activity and HDL structure. New links between cigarette smoke and coronary heart disease risk. Arterioscler Thromb. 1994; 14: 248-253. PMID: 8305416
27. Aseervatham GS, Sivasudha T, Jeyadevi R, Arul Ananth D. Environmental factors and unhealthy lifestyle influence oxidative stress in humans - an overview. Environ Sci Pollut Res Int. 2013; 20: 4356-4369. doi: 10.1007/s11356-013-1748-0 PMID: 23636598
28. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res. 2009; 50 Suppl: S145-S149. doi: 10.1194/jlr.R800036-JLR200 PMID: 18955731
29. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012; 51: 314-324. doi: 10.1016/j.plipres.2012.03.003 PMID: 22609245
30. Johnstone RAW, Plimmer JR. The Chemical Constituents of Tobacco and Tobacco Smoke. Chem Rev. 1959; 59: 885-936.
31. Witz G. Biological interactions of alpha,beta-unsaturated aldehydes. Free Radic Biol Med. 1989; 7: 333-349. PMID: 2673948
32. Feron VJ, Til HP, de Vrijer F, Woutersen RA, Cassee FR, van Bladeren PJ. Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment. Mutat Res. 1991; 259: 363-385. PMID: 2017217
33. Fullana A, Carbonell-Barrachina AA, Sidhu S. Comparison of volatile aldehydes present in the cooking fumes of extra virgin olive, olive, and canola oils. J Agric Food Chem. 2004; 52: 5207-5214. PMID: 15291498
34. DeJarnett N, Conklin DJ, Riggs DW, Myers JA, O'Toole TE, Hamzeh I, et al. Acrolein Exposure Is Associated With Increased Cardiovascular Disease Risk. J Am Heart Assoc. 2014; 3.
35. Izard C, Libermann C. Acrolein. Mutat Res. 1978; 47: 115-138. PMID: 415230
36. Stevens JF, Maier CS. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol Nutr Food Res. 2008; 52: 7-25. doi: 10.1002/mnfr.200700412 PMID: 18203133
37. Jairam VU, K.; Narayanaswami V. Pathophysiology of Lipoprotein Oxidation, Lipoproteins- Role in Health and Diseases. Biochem Gen and Mol Biol. 2012: 383-408.
38. Shao B, O'Brien K D, McDonald TO, Fu X, Oram JF, Uchida K, et al. Acrolein modifies apolipoprotein A-I in the human artery wall. Ann N Y Acad Sci. 2005; 1043: 396-403. PMID: 16037261
39. Shao B, Fu X, McDonald TO, Green PS, Uchida K, O'Brien KD, et al. Acrolein impairs ATP binding cassette transporter A1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I. J Biol Chem. 2005; 280: 36386-36396. PMID: 16126721
40. Srivastava S, Sithu SD, Vladykovskaya E, Haberzettl P, Hoetker DJ, Siddiqui MA, et al. Oral exposure to acrolein exacerbates atherosclerosis in apoE-null mice. Atherosclerosis. 2011; 215: 301-308. doi: 10.1016/j.atherosclerosis.2011.01.001 PMID: 21371710
41. Conklin DJ, Barski OA, Lesgards JF, Juvan P, Rezen T, Rozman D, et al. Acrolein consumption induces systemic dyslipidemia and lipoprotein modification. Toxicol Appl Pharmacol. 2010; 243: 1-12. doi: 10.1016/j.taap.2009.12.010 PMID: 20034506
42. Watanabe K, Nakazato Y, Saiki R, Igarashi K, Kitada M, Ishii I. Acrolein-conjugated low-density lipoprotein induces macrophage foam cell formation. Atherosclerosis. 2013; 227: 51-57. doi: 10.1016/j.atherosclerosis.2012.12.020 PMID: 23305793
43. Obama T, Kato R, Masuda Y, Takahashi K, Aiuchi T, Itabe H. Analysis of modified apolipoprotein B-100 structures formed in oxidized low-density lipoprotein using LC-MS/MS. Proteomics. 2007; 7: 2132-2141. PMID: 17549798
44. Yoshida M, Higashi K, Kobayashi E, Saeki N, Wakui K, Kusaka T, et al. Correlation between images of silent brain infarction, carotid atherosclerosis and white matter hyperintensity, and plasma levels of acrolein, IL-6 and CRP. Atherosclerosis. 2010; 211: 475-479. doi: 10.1016/j.atherosclerosis.2010.03.031 PMID: 20417516
45. Ishii T, Yamada T, Mori T, Kumazawa S, Uchida K, Nakayama T. Characterization of acrolein-induced protein cross-links. Free Radic Res. 2007; 41: 1253-1260. PMID: 17922343
46. Chadwick AC, Sahoo D. Functional characterization of newly-discovered mutations in human SR-BI. PLoS One. 2012; 7: e45660. doi: 10.1371/journal.pone.0045660 PMID: 23029167
47. Zhang X, Goncalves R, Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol. 2008; Chapter 14: Unit 14 11. doi: 10.1002/0471142735.im0815s83 PMID: 19016451
48. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193: 265-275. PMID: 14907713
49. Connelly MA, Klein SM, Azhar S, Abumrad NA, Williams DL. Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake. J Biol Chem. 1999; 274: 41-47. PMID: 9867808
50. Parathath S, Connelly MA, Rieger RA, Klein SM, Abumrad NA, De La Llera-Moya M, et al. Changes in plasma membrane properties and phosphatidylcholine subspecies of insect Sf9 cells due to expression of scavenger receptor class B, type I, and CD36. J Biol Chem. 2004; 279: 41310-41318. PMID: 15280390
51. Parathath S, Darlington YF, de la Llera Moya M, Drazul-Schrader D, Williams DL, Phillips MC, et al. Effects of amino acid substitutions at glycine 420 on SR-BI cholesterol transport function. J Lipid Res. 2007; 48: 1386-1395. PMID: 17372332
52. Macala LJ, Yu RK, Ando S. Analysis of brain lipids by high performance thin-layer chromatography and densitometry. J Lipid Res. 1983; 24: 1243-1250. PMID: 6631248
53. Mizel SB, Graff AH, Sriranganathan N, Ervin S, Lees CJ, Lively MO, et al. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol. 2009; 16: 21-28. doi: 10.1128/CVI.00333-08 PMID: 18987167
54. Sorci-Thomas MG, Parks JS, Kearns MW, Pate GN, Zhang C, Thomas MJ. High level secretion of wildtype and mutant forms of human proapoA-I using baculovirus-mediated Sf-9 cell expression. J Lipid Res. 1996; 37: 673-683. PMID: 8728328
55. Li HH, Thomas MJ, Pan W, Alexander E, Samuel M, Sorci-Thomas MG. Preparation and incorporation of probe-labeled apoA-I for fluorescence resonance energy transfer studies of rHDL. J Lipid Res. 2001; 42: 2084-2091. PMID: 11734582
56. Shao B. Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of HDL. Biochim Biophys Acta. 2012; 1821: 490-501. doi: 10.1016/j.bbalip.2011.11.011 PMID: 22178192
57. Xu S, Huang Y, Xie Y, Lan T, Le K, Chen J, et al. Evaluation of foam cell formation in cultured macrophages: an improved method with Oil Red O staining and DiI-oxLDL uptake. Cytotechnology. 2010; 62: 473-481. doi: 10.1007/s10616-010-9290-0 PMID: 21076992
58. Shao B, Heinecke JW. HDL, lipid peroxidation, and atherosclerosis. J Lipid Res. 2009; 50: 599-601. doi: 10.1194/jlr.E900001-JLR200 PMID: 19141435
59. Gillard BK, Chen YS, Gaubatz JW, Massey JB, Pownall HJ. Plasma factors required for human apolipoprotein A-II dimerization. Biochemistry. 2005; 44: 471-479. PMID: 15641771
60. de Beer MC, Durbin DM, Cai L, Jonas A, de Beer FC, van der Westhuyzen DR. Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI. J Lipid Res. 2001; 42: 309-313. PMID: 11181762
61. Liadaki KN, Liu T, Xu S, Ishida BY, Duchateaux PN, Krieger JP, et al. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J Biol Chem. 2000; 275: 21262-21271. PMID: 10801839
62. Nieland TJ, Xu S, Penman M, Krieger M. Negatively cooperative binding of high-density lipoprotein to the HDL receptor SR-BI. Biochemistry. 2011; 50: 1818-1830. doi: 10.1021/bi101657j PMID: 21254782
63. Gillotte-Taylor K, Boullier A, Witztum JL, Steinberg D, Quehenberger O. Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J Lipid Res. 2001; 42: 1474-1482. PMID: 11518768
64. Gugliucci A, Lunceford N, Kinugasa E, Ogata H, Schulze J, Kimura S. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Clin Chim Acta. 2007; 384: 105-112. PMID: 17632094
65. Tamamizu-Kato S, Wong JY, Jairam V, Uchida K, Raussens V, Kato H, et al. Modification by acrolein, a component of tobacco smoke and age-related oxidative stress, mediates functional impairment of human apolipoprotein E. Biochemistry. 2007; 46: 8392-8400. PMID: 17580963
66. Sakata K, Kashiwagi K, Sharmin S, Ueda S, Irie Y, Murotani N, et al. Increase in putrescine, amine oxidase, and acrolein in plasma of renal failure patients. Biochem Biophys Res Commun. 2003; 305: 143-149. PMID: 12732208